Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3678-3685

  Sarfo, Fred Stephen ^a   Phillips, Richard ^a,b   Asiedu, Kingsley ^c   Ampadu, Edwin ^d   Bobi, Nana ^e   Adentwe, E ^e   Lartey, Awuli ^a   Tetteh, Ishmael ^a   Wansbrough Jones, M ^f  

^a KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d National Buruli Ulcer Control Programme   (Ghana)

^e Tepa Government Hospital   (Ghana)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ACID FAST BACTERIUM; ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BODY WEIGHT; BURULI ULCER; CHILD; COMBINATION CHEMOTHERAPY; DEBRIDEMENT; DIZZINESS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; HUMAN; INFANT; LABORATORY DIAGNOSIS; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALAISE; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM ULCERANS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SKIN TRANSPLANTATION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WORLD HEALTH ORGANIZATION; WOUND DRESSING;

ADOLESCENT; ADULT; AGED; BURULI ULCER; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MYCOBACTERIUM ULCERANS; RIFAMPIN; STREPTOMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956129001     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00299-10     Document Type: Article

References (29)

1. Amofah, G., S. Asamoah, and C. Afram-Gyening. 1998. Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana. Trop. Doct. 28:81-83.
2. Bentoucha, A., J. Robert, H. Dega, N. Lounis, V. Jarlier, and J. Grosset. 2001. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 45:3109-3112.
3. Chauty, A., M. F. Ardant, A. Adeye, H. Euverte, A. Guedenon, C. Johnson, J. Aubry, E. Nuermberger, and J. Grosset. 2007. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob. Agents Chemother. 51:4029-4035.
4. Coutanceau, E., J. Decalf, A. Martino, A. Babon, N. Winter, S. T. Cole, M. L. Albert, and C. Demangel. 2007. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J. Exp. Med. 204:1395-1403.
5. Coutanceau, E., L. Marsollier, R. Brosch, E. Perret, P. Goossens, M. Tanguy, S. T. Cole, P. L. Small, and C. Demangel. 2005. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell. Microbiol. 7:1187-1196.
6. Debacker, M., J. Aguiar, C. Steunou, C. Zinsou, W. M. Meyers, and F. Portaels. 2005. Buruli ulcer recurrence, Benin. Emerg. Infect. Dis. 11:584-589.
7. Dega, H., A. Bentoucha, J. Robert, V. Jarlier, and J. Grosset. 2002. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother. 46:3193-3196.
8. Dega, H., J. Robert, P. Bonnafous, V. Jarlier, and J. Grosset. 2000. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 44:2367-2372.
9. Eddyani, M., M. Debacker, A. Martin, J. Aguiar, C. R. Johnson, C. Uwizeye, K. Fissette, and F. Portaels. 2008. Primary culture of Mycobacterium ulcerans from human tissue specimens after storage in semisolid transport medium. J. Clin. Microbiol. 46:69-72.
10. Etuaful, S., B. Carbonnelle, J. Grosset, S. Lucas, C. Horsfield, R. Phillips, M. Evans, D. Ofori-Adjei, E. Klustse, J. Owusu-Boateng, G. K. Amedofu, P. Awuah, E. Ampadu, G. Amofah, K. Asiedu, and M. Wansbrough-Jones. 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob. Agents Chemother. 49:3182-3186.
11. Evans, M. R., R. Phillips, S. N. Etuaful, G. Amofah, J. Adomako, O. Adjei, J. Dennis-Antwi, S. B. Lucas, and M. H. Wansbrough-Jones. 2003. An outreach education and treatment project in Ghana for the early stage of Mycobacterium ulcerans disease. Trans. R. Soc. Trop. Med. Hyg. 97:159-160.
12. Evans, M. R. W., S. N. Etuaful, G. Amofah, O. Adjei, S. Lucas, and M. H. Wansbrough-Jones. 1999. Squamous cell carcinoma secondary to Buruli ulcer. Trans. R. Soc. Trop. Med. Hyg. 93:63-64.
13. Havel, A., and S. R. Pattyn. 1975. Activity of rifampicin on Mycobacterium ulcerans. Ann. Soc. Belg. Med. Trop. 55:105-108.
14. Herbinger, K. H., O. Adjei, N. Y. Awua-Boateng, W. A. Nienhuis, L. Kunaa, V. Siegmund, J. Nitschke, W. Thompson, E. Klutse, P. Agbenorku, A. Schipf, S. Reu, P. Racz, B. Fleischer, M. Beissner, E. Fleischmann, K. Helfrich, T. S. van der Werf, T. Loscher, and G. Bretzel. 2009. Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin. Infect. Dis. 48:1055-1064.
15. Lefrancois, S., J. Robert, A. Chauffour, B. Ji, and V. Jarlier. 2007. Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin. Antimicrob. Agents Chemother. 51:645-650.
16. Marsollier, L., N. Honore, P. Legras, A. L. Manceau, H. Kouakou, B. Carbonnelle, and S. T. Cole. 2003. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob. Agents Chemother. 47:1228-1232.
17. Nienhuis, W. A., Y. Stienstra, W. A. Thompson, P. C. Awuah, K. M. Abass, W. Tuah, N. Y. Awua-Boateng, E. O. Ampadu, V. Siegmund, J. P. Schouten, O. Adjei, G. Bretzel, and T. S. van der Werf. 2010. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375:664-672.
18. Pahlevan, A. A., D. J. M. Wright, C. Andrews, K. M. George, P. L. C. Small, and B. M. Foxwell. 1999. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J. Immunol. 163:3928-3935.
19. Phillips, R., F. S. Sarfo, F. Osei-Sarpong, and M. Wansbrough-Jones. 2006. Clinical response and bacterial killing during antibiotic treatment of Mycobacterium ulcerans disease, p. 60-61. http://www.who.int/buruli/information/ en/Abstracts.
20. Phillips, R. O., F. S. Sarfo, F. Osei-Sarpong, A. Boateng, I. Tetteh, A. Lartey, E. Adentwe, W. Opare, K. B. Asiedu, and M. Wansbrough-Jones. 2009. Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer. J. Clin. Microbiol. 47:924-926.
21. Portaels, F., H. Traore, K. De Ridder, and W. M. Meyers. 1998. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob. Agents Chemother. 42:2070-2073.
22. Revill, W. D., R. H. Morrow, M. C. Pike, and J. Ateng. 1973. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet ii:873-877.
23. Shepard, C. C., and D. H. McRae. 1968. A method for counting acid-fast bacteria. Int. J. Lepr. Other Mycobact. Dis. 36:78-82.
24. Simonet, V. 2008. Prevention of disability in Buruli ulcer: basic rehabilitation. http://whqlibdoc.who.int/hq/2008/WHO-HTM-NTD-IDM-GBUI-2008.1- eng.pdf.
25. Stanford, J. L., and I. Phillips. 1972. Rifampicin in experimental Mycobacterium ulcerans infection. J. Med. Microbiol. 5:39-45.
26. Thangaraj, H. S., O. Adjei, B. W. Allen, F. Portaels, M. R. W. Evans, D. K. Banerjee, and M. H. Wansbrough-Jones. 2000. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J. Antimicrob. Chemother. 45:231-233.
27. Torrado, E., S. Adusumilli, A. G. Fraga, P. L. Small, A. G. Castro, and J. Pedrosa. 2007. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect. Immun. 75:3979-3988.
28. Torrado, E., A. G. Fraga, A. G. Castro, P. Stragier, W. M. Meyers, F. Portaels, M. T. Silva, and J. Pedrosa. 2007. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect. Immun. 75:977-987.
29. Wansbrough-Jones, M., and R. Phillips. 2006. Buruli ulcer: emerging from obscurity. Lancet 367:1849-1858.